News

This expands the commercialization agreement between Intercell and Novartis to these territories, which previously were not covered by the initial marketing and distribution agreement for Intercell’s Japanese encephalitis

The grant provides $500,000 for the next 24 months and will allow the company to continue developing its platform technology, and to fund preclinical studies of its early

For the fourth quarter, company expects to report GAAP diluted EPS of $0.18. Preliminary GAAP EPS results for the quarter and full year include approximately $0.05 related to

From 1983 to 2007, Bryant held various worldwide commercial operations roles with Abbott Laboratories including: vice president of Abbott Vascular for Asia/Japan, vice president of Abbott Molecular Global

Leena Doshi, president of Doshi Diagnostic, said: “The Fonar Upright Multi-Position MRI is a perfect complement to existing closed high field and open low field magnets already in

According to SurgiQuest, its technology offers superior access during minimally invasive surgical procedures because it allows the surgeon to operate with an unprecedented degree of freedom. The AirSeal

Abbott has opened a new pharmaceutical analytical research laboratory in Singapore’s Biopolis research park. This new facility is Abbott’s first pharmaceutical research and development site in Southeast Asia.

The study was designed to elicit potential adverse effects from a single, very large dose of hGH-CTP, also known as MOD-4023. No adverse effects were observed, and the

Oscient filed this lawsuit under the Hatch-Waxman Act in response to the Paragraph IV certification notice received by the company from Lupin advising the company of the filing